Effective August 2, 2022, mdxhealth has acquired the Oncotype DX GPS (Genomic Prostate Score) test from Exact Sciences. To help ensure a smooth transition for patients, continue to place orders for this test through the existing Exact Sciences portal until further notice. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the Oncotype DX GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the following press release. Questions? Email: gps@mdxhealth.com

Colorectal Cancer Blood

Exact Sciences is developing a blood-based screening method for colorectal cancer. Samples collected from the BLUE-C clinical trial will be used to establish the performance characteristics of this test. A blood test will be another addition to our portfolio of colorectal cancer screening options to reach the 44 million Americans who need to be screened for colorectal cancer.